



# CP-LC-0729

## Product number 860799


CP-LC-0729 is manufactured and distributed under license from Certest Biotech S.L. CP-LC-0729 is an ionizable lipid that successfully encapsulates mRNA, saRNA, and circRNA. In vivo studies carried out in mice show that lipid nanoparticle (LNP) formulations using ionizable lipid CP-LC-0729 exhibit increased mRNA expression, similar antibody and Th1 immune responses, and favorable safety profiles compared to industry-leading formulations. Like other industry-leading formulations, LNPs formulated with CP-LC-0729 have shown a primary biodistribution in the liver.

Lyophilized LNPs formulated with CP-LC-0729 stored in refrigerated conditions (4°C) exhibited much improved stability profiles compared to industry-leading liquid formulations stored at 4°C. After twelve months of storage, when comparing antibody response of lyophilized LNPs formulated with CP-LC-0729 stored at 4°C to industry-leading liquid LNP formulations stored at -80°C, the antibody responses were similar.

### Key product features include:

- Shows good encapsulation and expression of circRNA and saRNA
- Improved mRNA expression compared to industry-leading formulations
- Improved stability of lyophilized formulations compared to industry-leading formulations
- Hepatic delivery of nucleic acid payloads

**certest**



## Product information

### Physical and chemical properties

CAS number <sup>1</sup> 3040858-60-1

Molecular weight 740.23

Purity and material grade >99%, Research-Use-Only, not intended for use in humans

Storage temperature -20 °C

Application Hepatic delivery of nucleic acid cargos (mRNA, circRNA, saRNA, etc.) via lipid nanoparticle formulations (LNPs)

pKa (measured by TNS fluorescence titration) 6.78


<sup>1</sup>CAS is a registered trademark of the American Chemical Society

# CP-LC-0729

Product number 860799


**Figure 1**

% Metabolized ionizable lipid (biodegradability)




**Figure 2**

Relative Luc expression vs industry-leading LNP formulations




**Figure 3**

Expression of circ-RNA



**Figure 4**

Expression of saRNA



**Table 1**

Lipid nanoparticles formulated with 50 mol% CP-LC-0729, 10 mol% DOPE, 38.5 mol% cholesterol, and 1.5 mol% DMG-PEG2000 with an N/P 6 exhibit the following physicochemical attributes.

Physicochemical attributes	
Size	70-110 <sup>1</sup> nm
Polydispersity	< 0.2
Zeta potential	Near neutral
Encapsulation efficiency	> 85%

<sup>1</sup> dependent on payload size and fluid flow processing parameters

**Did you know that Avanti Research™ offers formulations services?**

Not sure how to formulate with CP-LC-0729?

Want to perform feasibility studies without equipment investment?

Avanti Research formulations experts are ready to help you turn your product ideas into reality. We provide support and guidance from initial concept through to full-scale production!

**Non-warranty**

The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Unless otherwise stated, any trademarks identified herein are trademarks of the Croda group of companies.

©2025 Croda International.

CPDS051v1 EN 05/25